Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Xilio Therapeutics (XLO) EBIAT (2024 - 2025)

Xilio Therapeutics' EBIAT history spans 2 years, with the latest figure at -$1.9 million for Q3 2025.

  • For Q3 2025, EBIAT rose 86.24% year-over-year to -$1.9 million; the TTM value through Sep 2025 reached -$42.7 million, changed N/A, while the annual FY2024 figure was -$58.2 million, 23.77% up from the prior year.
  • EBIAT for Q3 2025 was -$1.9 million at Xilio Therapeutics, up from -$14.4 million in the prior quarter.
  • Across five years, EBIAT topped out at -$1.9 million in Q3 2025 and bottomed at -$17.2 million in Q1 2024.